Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa

<p>Background: In sub-Saharan Africa, severely immunocompromised HIV-infected individuals have high mortality (10%) from infections shortly after starting antiretroviral therapy (ART). </p><p> Methods: The REALITY factorial open-label trial (ISRCTN43622374) randomized Ugandan/Zimb...

Full description

Bibliographic Details
Main Authors:	Hakim, J, Musiime, V, Szubert, A, Mallewa, J, Siika, A, Agutu, C, Walker, S, Pett, S, Bwakura-Dangarembizi, M, Lugemwa, A, Kaunda, S, Karoney, M, Musoro, G, Kabahenda, S, Nathoo, K, Maitland, K, Griffiths, A, Thomason, M, Kityo, C, Mugyenyi, P, Prendergast, A, Walker, A, Gibb, D
Format:	Journal article
Published:	Massachusetts Medical Society 2017

Similar Items

Late presentation with HIV in Africa: phenotypes, risk and risk stratification in the REALITY trial
by: Siika, A, et al.
Published: (2018)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
by: Bwakura-Dangarembizi, M, et al.
Published: (2015)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
by: Kityo, C, et al.
Published: (2018)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
by: Szubert, A, et al.
Published: (2015)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
by: Prendergast, A, et al.
Published: (2016)

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
by: Mallewa, J, et al.
Published: (2018)

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial
by: Post, F, et al.
Published: (2018)

The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa
by: Walker, SM, et al.
Published: (2020)

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa
by: Riitho, V, et al.
Published: (2024)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
by: Crook, A, et al.
Published: (2016)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
by: Cissy Kityo, et al.
Published: (2018-12-01)

Opportunities for improving the efficiency of paediatric HIV treatment programmes.
by: Revill, P, et al.
Published: (2015)

Marginal structural models for repeated measures where intercept and slope are correlated: an application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy
by: Farmer, R, et al.
Published: (2020)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial
by: Szubert, A, et al.
Published: (2017)

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
by: Kekitiinwa, A, et al.
Published: (2013)

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe
by: Prendergast, A, et al.
Published: (2019)

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
by: Musoke, P, et al.
Published: (2015)

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
by: Bwakura-Dangarembizi, M, et al.
Published: (2014)

Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy
by: Prendergast, A, et al.
Published: (2016)

Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.
by: Fillekes, Q, et al.
Published: (2014)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
by: Walker, A, et al.
Published: (2012)

Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy.
by: Ruth E Farmer, et al.
Published: (2020-01-01)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
by: Hakim, J, et al.
Published: (2017)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
by: Hakim, J, et al.
Published: (2017)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial.
by: Alexander J Szubert, et al.
Published: (2017-11-01)

The impact of viraemia on inflammatory biomarkers and CD4 cell subpopulations in HIV-infected children in sub-Saharan Africa
by: Prendergast, AJ, et al.
Published: (2021)

HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe.
by: Jaganath, D, et al.
Published: (2014)

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.
by: Picat, M, et al.
Published: (2013)

Improved adherence to antiretroviral therapy observed among HIV-infected children whose caregivers had positive beliefs in medicine in Sub-Saharan Africa
by: Abongomera, G, et al.
Published: (2016)

Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.
by: Prendergast, A, et al.
Published: (2011)

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
by: Musiime, V, et al.
Published: (2010)

Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children
by: Kekitiinwa, A, et al.
Published: (2016)

Virologic response to first-line efavirenz- or nevirapine-based anti-retroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017)

Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status
by: Pett, SL, et al.
Published: (2020)

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
by: Fillekes, Q, et al.
Published: (2011)

Ethical and legal constraints to children’s participation in research in Zimbabwe: experiences from the multicenter pediatric HIV ARROW trial
by: Bwakura-Dangarembizi Mutsa, et al.
Published: (2012-07-01)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017)

DART and laboratory monitoring of HIV treatment Reply
by: Walker, A, et al.
Published: (2010)

Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
by: Munderi, P, et al.
Published: (2010)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
by: Ross, LL, et al.
Published: (2019)